Study record
Mitochondrial peptides-appropriate options for therapeutic exploitation
Popov LD · Cell Tissue Res · 2019
ReviewSeveralEvidence tier R
What this study reported
Reviewed the biological effects of mitochondrial-derived peptides including MOTS-c, β-amyloid accumulation in mitochondria, and mitochondria-targeting peptides as delivery vehicles.
Limitations
Broad review in which MOTS-c is one of several topics; the abstract gives no MOTS-c-specific findings.
Study record
| Study model | Review |
|---|---|
| Substance studied | SeveralMore than one of these is central to the paper (common for reviews). |
| Species | Not reported |
| System studied | Review of mitochondrial-derived peptides, mitochondrial β-amyloid and mitochondria-targeting peptides |
| Population | Not reported |
| Design | Narrative review |
| Sample size as reported | Not reported |
| Control group | Not reported |
| Route (data field only) | Not reported |
| Endpoints measured | biological effects of humanin, humanin-like peptides and MOTS-c |
| Pathways measured | Not reported |
| Research areas | Mitochondrial biology · Nervous system |
| Evidence tier | R — Review (context, not evidence) |
| Publication types | Journal Article, Review |
Appraisal
Each dimension is recorded separately and never combined into a single score. A study can be well controlled and still tell you little about people.
- Relevance to MOTS-c
- Indirect
- Model applicability
- n/a
- Sample size
- n/a
- Controls
- n/a
- Outcome validity
- n/a
- Support for its own conclusion
- n/a
Provenance
- Bibliographic fields retrieved from PubMed E-utilities efetch (title, journal, date, authors, DOI) on 2026-11-11.
- Annotated from the published abstract.
- Editorial review: approved (2026-11-11).
- Classification follows the site methodology; the record describes the study, not what MOTS-c does in people.